BOEHRINGER-INGELHEIM
3.8.2022 12:07:11 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe17.11.2026 09:00:00 CET | Press release
European Technology Group (ETG), a long-term oriented European GovTech platform, welcomes Tractivity, a leading stakeholder relationship management software provider in Europe, to its family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117911743/en/ Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe The transaction marks the next stage of Tractivity’s development after sustained growth. The company serves more than 100 organisations across energy, utilities, healthcare, central and local government, regulators and transport in Europe. As part of ETG, Tractivity will build on its established brand, long-standing customer trust and clear product focus. ETG adds resources and know-how to accelerate product development and invest in AI capabilities that make stakeholder engagement more efficient. ETG’s European network will support Tractivity’s expansion across Europe and among en
Aqara Expands Smart Lighting Portfolio, Showing the Spatial Intelligence Control With the Lighting Transfer17.11.2026 09:00:00 CET | Press release
Six new lighting products bring vibrant indoor and outdoor illumination, seamless Apple Home compatibility, dual-protocol connection, and personalized automation powered by Aqara numerous portfolio Aqara, a global leader and pioneer in IoT, today announced the global launch of six new smart lighting products showcased at IFA 2026: the Floor Lamp T1, LED Downlight T2, LED Strip T2, LED Bulb T2 E12/E14, Outdoor String Lights H1, and Permanent Outdoor Lights H1. Spanning everyday illumination, immersive entertainment, and outdoor decoration, the expanded portfolio pairs advanced lighting technology and flexible connectivity with Aqara’s extensive range of smart home devices to create more responsive, personalized living spaces. Together, they bring Aqara’s vision of Spatial Intelligence into the home. In addition, all these six products can be seamlessly integrated into the Apple Home ecosystem, offering smooth across-platform usage experience. This press release features multimedia. View
FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 07:30:00 CET | Press release
Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
